. BVT.X Significantly Reduced Plasma Insulin without Affecting Blood Glucose, Food Intake, Body Weight, % Body Fat, Locomotor Activity, or Energy Expenditure
Male ob/ob mice (n = 7 per treatment, mean body weight = 68 g, mean fasting blood glucose = 268 mg/dl) individually housed in CLAMS chambers that produced continuous measures of food intake, activity, and energy expenditure were anesthetized, %body fat was determined using DEXA (day 0) and then mice were implanted with subcutaneous osmotic minipumps filled with saline or the 5-HT 2C R agonist BVT.X (40 mg/kg/day for 14 days).
(A and B) BVT.X treatment (black bars) significantly reduced fasting plasma insulin (12 hr dark cycle fast) by 45% from baseline (insulin day -2 = 12.7 ng/ml, day 14 = 6.9 ng/ml; t(6)=3.8, p<0.01) (A), but did not effect fasting blood glucose (B). Two weeks of saline treatment (white bars) did not significantly alter either fasting plasma insulin or blood glucose. (E) No difference in %body fat were observed following 14 days of BVT.X or saline treatment (black bars) compared to pre-treatment levels (white bars).
(F and G) BVT.X also did not alter light (white bars) or dark (hatched bars) cycle locomotor activity (F), or light (white bars) or dark (hatched bars) cycle energy expenditure (as measured by mean daily VO 2 ) compared to saline treatment (G).
Data are presented as mean ± SEM, **p<0.01.
Figure S2. Confirmation that Acute and Chronic Administration of Subanorectic Dose of 5-HT 2C R Agonist mCPP Does Not Affect Food Intake or Body Weight in Mice
(A) Ad libitum fed male DIO (n = 12, mean body weight = 31 g), Mc3r KO (n = 12, mean body weight = 33 g), and Mc4r KO mice (n = 12, mean body weight = 37 g) mice exhibited no differences in dark cycle 2 hr chow intake when treated with either saline (white bars) or mCPP (1 mg/kg, i.p.; black bars).
(B-E) Like DIO mice (see Figure 1C-1D ), Mc3r KO (B and C) and Mc4r KO mice (D and E) (n = 10-12 per genotype) showed no differences in daily food intake or body weight when implanted with a subcutaneous osmotic minipump filled with either saline (open circles) or a subanorectic dose of mCPP (1 mg/kg/day for 14 days, s.c.; closed circles).
Data are presented as mean ± SEM. 
Figure S4. mCPP Pretreatment Prior to a Glucose Load Significantly Increased FOS-IR in the Intermediolateral Cell Column (IML) in WT, but Not Mc4r KO, Mice
Brain tissue from adult male WT and Mc4r KO littermates pretreated with saline or mCPP (1 mg/kg, i.p.) and treated with glucose (as described in Figure S3 ) was processed for FOS-IR (indicated by black nuclear stain) to investigate neuronal activation patterns in the IML, a region expressed at vertebral levels T1 -L2 which mediates sympathetic innervation of the body. Brain tissue from adult male WT and Mc4r KO littermates pretreated with saline or mCPP (1 mg/kg, i.p.) and treated with glucose (as described in Figure S3 ) was processed for FOS-IR (indicated by black nuclear stain) to investigate neuronal activation patterns in regions associated with autonomic outflow expressing MC4Rs. Compared to saline treatment, mCPP significantly increased FOS-IR in the paraventricular nucleus of the hypothalamus (PVH) (A-D), the arcuate nucleus of the hypothalamus (ARC) and ventromedial nucleus of the hypothalamus (VMH) (E-H), VMH and dorsomedial nucleus of the hypothalamus (DMH) (I-L), the lateral hypothalamic area (LHA) (M-P), and the dorsal motor nucleus of the vagus (DMV) and nucleus of the solitary tract (NTS) (Q-T) in both WT and Mc4r KO mice. These data are in contrast to those observed in the IML ( Figure S4 ), and suggest that FOS-IR activation in these brain regions does not require functional MC4Rs. Scale bar in (D) = 50 µM and applies to (A)-(D); scale bar in (T) = 100 µM and applies to all other photomicrographs.
